Mogroside I E1

CAS No. 88901-39-7

Mogroside I E1( —— )

Catalog No. M26302 CAS No. 88901-39-7

Mogroside I E1 is a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 249 Get Quote
10MG 426 Get Quote
25MG 683 Get Quote
50MG 888 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Mogroside I E1
  • Note
    Research use only, not for human use.
  • Brief Description
    Mogroside I E1 is a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener.
  • Description
    Mogroside I E1 is a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    88901-39-7
  • Formula Weight
    638.883
  • Molecular Formula
    C36H62O9
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (52.17 mM)
  • SMILES
    [H][C@@]1(CC[C@@]2(C)[C@]3([H])CC=C4[C@@]([H])(CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C4(C)C)[C@]3(C)[C@H](O)C[C@]12C)[C@H](C)CC[C@@H](O)C(C)(C)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jingyuan Xu, et al. Organ-Specific Metabolic Shifts of Flavonoids in Scutellaria baicalensis at Different Growth and Development Stages. Molecules. 2018 Feb 15;23(2):428.
molnova catalog
related products
  • Docosahexaenoic Acid

    Docosahexaenoic Acid (DHA) is an essential fatty acid and an omega-3 fatty acid abundant in brain and retina.

  • Poloxamer 407

    Poloxamer 407 is a nonionic surfactant.

  • Uprosertib

    Uprosertib (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.